1. Generics Bulletin
  2. >>Business

Viatris: Watch Out For Potential Complex Injectable Launches In 2023

As Firm Welcomes Generics ‘Momentum We Have Never Seen Before’

 
• By Dean Rudge

Viatris has again the lauded the potential of its complex injectables and steriles pipeline, as it looks to build a business generating revenues of up to $1bn per year within the next five years.

NWW Binoculaurs
• Source: Shutterstock

Viatris has guided for certain of its pipeline of complex injectable and sterile products in the US to come to market “if we are optimistic later this year or early next year,” as it continues to aim towards building a franchise worth, it believes, at least $1bn per year in peak net sales by 2027 or 2028.

The company has eight first-to-market opportunities that are currently under regulatory review from within its complex injectable/steriles pipeline, including a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By Dave Wallace

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership

 
• By Dean Rudge

Ahead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.